PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while Biotechnology median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
8.54%
Cost growth of 8.54% versus flat Biotechnology costs. Walter Schloss would verify cost control.
-83.05%
Gross profit decline while Biotechnology median is -0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
R&D reduction while Biotechnology median is -2.11%. Seth Klarman would investigate competitive implications.
28.45%
G&A change of 28.45% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while Biotechnology median is -0.16%. Seth Klarman would investigate advantages.
-7.93%
Total costs reduction while Biotechnology median is -0.72%. Seth Klarman would investigate advantages.
-100.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
8.54%
D&A change of 8.54% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
7.52%
EBITDA growth exceeding 1.5x Biotechnology median of 2.98%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth exceeding 1.5x Biotechnology median of 1.65%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Other expenses reduction while Biotechnology median is -4.23%. Seth Klarman would investigate advantages.
7.01%
Pre-tax income growth exceeding 1.5x Biotechnology median of 3.97%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
7.01%
Net income growth exceeding 1.5x Biotechnology median of 3.08%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth near Biotechnology median of 9.09%. Charlie Munger would verify industry dynamics.
8.82%
Diluted EPS growth near Biotechnology median of 8.82%. Charlie Munger would verify industry dynamics.
0.91%
Share count reduction below 50% of Biotechnology median of 0.80%. Jim Chanos would check for issues.
0.91%
Diluted share reduction below 50% of Biotechnology median of 0.88%. Jim Chanos would check for issues.